WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today that data from a study (“Safety and efficacy of ECG-triggered muscular counterpulsation for hemodynamic improvement of cardiac function”) presented at the recently convened Annual Congress of the Swiss Society of Cardiology demonstrates that “MCP (muscular counterpulsation) is safe and efficient for improving cardiac function in patients with coronary artery disease (CAD). One of the study’s investigators was Prof. Beat Walpoth, Director of Cardiovascular Research, Clinical and Experimental, at University Hospital in Geneva, Switzerland.
